Chugai Secures Licensing Deal with Roche for Hypertension Drug Zilebesiran in Japan.

Cerevel Therapeutics Reveals Encouraging Initial Outcomes from Phase 3 Supplementary Study of Tavapadon in Parkinson’s Disease Patients.

D2M Biotherapeutics has initiated a Phase 1 trial by administering the first dose of DM919, an innovative MICA/B antibody, aimed at treating individuals with advanced solid tumors.

Pathios Therapeutics Secures $25M in Initial Series B Funding Round to Propel Unique Immunotherapy Strategy into Clinical Trials.

GV20 Therapeutics Reveals Partnership for Clinical Study to Test GV20-0251, an Innovative Antibody Targeting New Immune Checkpoint IGSF8, Together with KEYTRUDA® (pembrolizumab).

Results from the Phase 3 SELECT-GCA trial indicate that Upadacitinib (RINVOQ®) offers promising outcomes for individuals with Giant Cell Arteritis.

NMPA Greenlights IND Submission for Initial Clinical Trial Using HLX53 Anti-TIGIT Fc Fusion Protein in Conjunction with HANSIZHUANG and HANBEITAI for Early Treatment in Patients with Advanced or Metastatic Liver Cancer.

Vertex Pharmaceuticals reports advancements in its suzetrigine pain treatment program. Suzetrigine, also known as VX-548, is an oral NaV1.8 inhibitor that could be the first new painkiller class for acute and neuropathic pain in two decades.

Telomir Pharmaceuticals Reveals Promising Early Results for Anti-Aging Medication Telomir-1 at a Press Event in Washington, D.C.

Subcutaneous Ocrevus, by Genentech, Shows Almost Total Control of Clinical Relapses and Brain Lesions Over a Year in Progressive and Relapsing MS Cases.

Ventus Therapeutics Releases Findings of Phase 1 Study for VENT-02, an Innovative Oral Brain-Targeting NLRP3 Inhibitor.

Press Announcement: Latest 48-week stage 2 findings on frexalimab indicate promising consistent effectiveness in treating multiple sclerosis.